Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells $29,776,095.30 in Shares

Eli Lilly and Company (NYSE:LLY – Get Rating) largest shareholder, Lilly Endowment Inc, sold 89,458 shares of the company in a trade on Thursday, July 28. The shares were sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the completion of the sale, the insider now owns 103,875,441 shares of the company, valued at approximately $34,574,940,536.85. The sale was disclosed in a legal filing with the SEC, accessible via this link. Large shareholders who own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Tuesday July 26, Lilly Endowment Inc sold 1,601 shares of Eli Lilly and shares. The stock was sold at an average price of $332.52, for a total transaction of $532,364.52.
  • On Friday July 15, Lilly Endowment Inc sold 17,310 shares of Eli Lilly and shares. The stock was sold at an average price of $332.76, for a total transaction of $5,760,075.60.
  • On Wednesday, July 6, Lilly Endowment Inc sold 177,243 Eli Lilly shares and shares. The stock was sold at an average price of $330.28, for a total transaction of $58,539,818.04.
  • On Monday, June 27, Lilly Endowment Inc sold 41,857 Eli Lilly shares and shares. The stock was sold at an average price of $329.05, for a total transaction of $13,773,045.85.
  • On Friday, June 24, Lilly Endowment Inc sold 215,000 Eli Lilly shares and stock. The stock was sold at an average price of $324.31, for a total transaction of $69,726,650.00.
  • On Wednesday, June 22, Lilly Endowment Inc sold 210,000 Eli Lilly shares and shares. The stock was sold at an average price of $306.84, for a total transaction of $64,436,400.00.
  • On Friday May 27, Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock. The stock was sold at an average price of $318.98, for a total transaction of $63,796,000.00.
  • On Wednesday, May 25, Lilly Endowment Inc sold 41,610 shares of Eli Lilly and shares. The stock was sold at an average price of $308.95, for a total value of $12,855,409.50.
  • On Monday, May 23, Lilly Endowment Inc sold 118,856 Eli Lilly shares and shares. The stock was sold at an average price of $302.73, for a total value of $35,981,276.88.
  • On Wednesday, May 18, Lilly Endowment Inc sold 700 shares of Eli Lilly and shares. The stock was sold at an average price of $302.00, for a total value of $211,400.00.

Eli Lilly and Stock down 1.1%

A d Weekly Investor Alerts

Will these 5 stocks explode?

Looking for the next disruptive Microcap stocks? These companies will be releasing their quarterly results very soon… And we’ve found 5 microcap stocks that could experience a surge in share price.

NYSE LLY traded at $3.68 during Friday trading hours, hitting $327.12. 54,305 shares of the company were traded, with an average volume of 2,896,932. Eli Lilly and Company has a one-year low of $220.20 and a one-year high of $335.33. The company has a debt ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The company’s 50-day moving average is $315.23 and its two-hundred-day moving average is $286.29. The company has a market capitalization of $310.82 billion, a price-to-earnings ratio of 49.01, a growth price-to-earnings ratio of 2.35 and a beta of 0.37.

Eli Lilly and (NYSE:LLY – Get Rating) last released their quarterly results on Thursday, April 28. The company reported earnings per share of $2.62 for the quarter, beating analyst consensus estimates of $2.32 by $0.30. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The company posted revenue of $7.81 billion in the quarter, versus a consensus estimate of $7.29 billion. In the same quarter a year earlier, the company posted EPS of $1.87. The company’s revenue increased 14.8% year over year. On average, analysts expect Eli Lilly and Company to post EPS of 8.31 for the current fiscal year.

Eli Lilly and announces a dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 9. Shareholders of record on Monday August 15 will receive a dividend of $0.98 per share. This represents a dividend of $3.92 on an annualized basis and a yield of 1.20%. The ex-dividend date is Friday, August 12. Eli Lilly’s dividend payout ratio (DPR) is currently 58.07%.

A Wall Street analyst gives his opinion

Several brokerages weighed in on LLY. Barclays raised its price target on Eli Lilly and $333.00 to $355.00 and gave the stock an “overweight” rating in a Thursday, July 7 report. Morgan Stanley raised its price target on Eli Lilly and from $369.00 to $395.00 and gave the company an “overweight” rating in a Friday, July 8 research note. StockNews.com upgraded Eli Lilly from a “buy” rating to a “strong buy” rating in a Friday, July 1 research rating. UBS Group raised its price target on Eli Lilly and to $335.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Mizuho raised its price target on Eli Lilly and from $315.00 to $356.00 in a Monday, May 2 research note. Three investment analysts gave the stock a hold rating, fifteen gave the stock a buy rating and one gave the stock a high buy rating. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $316.06.

Hedge funds weigh on Eli Lilly and

A number of large investors have recently bought and sold shares of LLY. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and 1.8% in the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company valued at $20,183,695,000 after purchasing an additional 1,219,424 shares in the last quarter. State Street Corp increased its holdings of Eli Lilly shares and 2.5% in the 4th quarter. State Street Corp now owns 33,929,864 shares of the company valued at $9,372,107,000 after purchasing an additional 813,983 shares in the last quarter. Capital World Investors increased its holding of Eli Lilly shares by 17.0% in the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company valued at $6,402,838,000 after purchasing an additional 3,242,548 shares in the last quarter. Geode Capital Management LLC increased its holdings in Eli Lilly shares and by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company valued at $4,059,130,000 after purchasing an additional 409,009 shares in the last quarter. Lastly, Capital International Investors increased its holding of Eli Lilly shares by 30.5% in the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company valued at $2,532,024,000 after purchasing an additional 2,063,557 shares in the last quarter. Institutional investors and hedge funds own 82.75% of the company’s shares.

Eli Lilly and Company Profile

(Get an assessment)

Eli Lilly and Company discovers, develops and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; and Jardiance, Trajenta and Trulicity for type 2 diabetes.

Featured articles

Insider buying and selling by quarter for Eli Lilly and (NYSE:LLY)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Eli Lilly and now?

Before you consider Eli Lilly and, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market took over… and Eli Lilly and didn’t make the list.

Although Eli Lilly currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

About Virginia Ahn

Check Also

Live update: UK manufacturing falls to lowest level since June 2020

This week, the Conservative leadership race caravan is moving from parliament to members across the …